News
BPMC
93.00
+2.50%
2.27
The Analyst Verdict: Blueprint Medicines In The Eyes Of 7 Experts
Blueprint Medicines has been analyzed by 7 analysts in the last three months. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. The average 12-month price target for Blueprint Medicines is $97.43. The biopharmaceutical company is focused on improving the lives of patients with rare diseases.
Benzinga · 15h ago
Stifel Nicolaus Sticks to Their Buy Rating for Blueprint Medicines (BPMC)
TipRanks · 16h ago
BLUEPRINT MEDICINES CORP <BPMC.O>: STIFEL RAISES TARGET PRICE TO $130 FROM $120
Reuters · 16h ago
Blueprint Medicines Price Target Maintained With a $125.00/Share by HC Wainwright & Co.
Dow Jones · 16h ago
HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $125 Price Target
Benzinga · 17h ago
Analysts Offer Insights on Healthcare Companies: Hookipa Pharma (HOOK), Praxis Precision Medicines (PRAX) and Blueprint Medicines (BPMC)
TipRanks · 17h ago
Blueprint Medicines Price Target Maintained With a $97.00/Share by Needham
Dow Jones · 18h ago
Needham Reiterates Buy on Blueprint Medicines, Maintains $97 Price Target
Benzinga · 18h ago
Barclays Sticks to Its Hold Rating for Blueprint Medicines (BPMC)
TipRanks · 19h ago
Blueprint Medicines Corporation: A Strong Buy on Robust Pipeline and Market Potential for Mast Cell Disease Treatments
TipRanks · 23h ago
Blueprint Medicines: Buy Rating Affirmed on BLU-808 Prospects and Strong Ayvakit Sales Forecast
TipRanks · 1d ago
Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)
TipRanks · 4d ago
Weekly Report: what happened at BPMC last week (0415-0419)?
Weekly Report · 4d ago
Weekly Report: what happened at BPMC last week (0408-0412)?
Weekly Report · 04/15 09:26
S&P 500 Futures Fall In Premarket Trading; CarMax, Fastenal Lag
U.S. Stock markets set to open in two hours. S&P 500 futures were down 0.39% in pre-market trading. Stocks in Asia were mixed overnight. Bitcoin rose 0.74% to $70,541. Brent crude oil futures were up 0.41%.
Barron‘s · 04/11 11:31
Decoding 6 Analyst Evaluations For Blueprint Medicines
Blueprint Medicines Corp is a biopharmaceutical company. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. 6 analysts have shared their evaluations of Blueprint Medicines in the last three months. The firm has an average price target of $95.67 for the company. It has a 12-month revenue growth of 85.55%.
Benzinga · 04/10 19:00
Blueprint Medicines Price Target Maintained With a $114.00/Share by JMP Securities
Dow Jones · 04/10 15:12
JMP Securities Reiterates Market Outperform on Blueprint Medicines, Maintains $114 Price Target
Benzinga · 04/10 15:02
Blueprint Medicines Buy Rating: Promising BLU-222 Efficacy and Strong Financial Outlook
TipRanks · 04/09 20:25
More
Webull provides a variety of real-time BPMC stock news. You can receive the latest news about Blueprint Medicines Corp through multiple platforms. This information may help you make smarter investment decisions.
About BPMC
Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.